US Congress Senate Bill 2004 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on June 27 2019 - 25% progression, died in committee
Action: 2019-06-27 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]

Reduces the marketing exclusivity period for biological drug products from 12 to 7 years and establishes policies and programs designed to increase access to prescription insulin. Specifically, the bill requires the Centers for Disease Control and Prevention to award grants to states to create insulin card programs, which provide uninsured or underinsured individuals with insulin at no cost for specified time periods. Payments for insulin prescriptions made through the program must count toward an underinsured individual’s health plan deductible. Further, the Department of Health and Human Services (HHS) must collect annual fees from insulin manufacturers, based on each manufacturer’s market share, equal to the total estimated expenditures under the insulin grants program. Subject to certain exceptions, the bill also establishes an excise tax on insulin manufacturers when the price of an insulin product spikes. The tax amount is a specified percentage of the revenue a manufacturer received as a result of the price spike. The tax amount increases in tiers based on the percentage of the price spike for that product.

Emergency Access to Insulin Act of 2019

Sen. Tina Smith [D-MN]

Sen. Kevin Cramer [R-ND]

Date	Chamber	Action
2019-06-27	Senate	Read twice and referred to the Committee on Finance.

HB4010 (Same As) 2019-07-26 - Referred to the Subcommittee on Health.

Type	Source
Summary	https://www.congress.gov/bill/116th-congress/senate-bill/2004/all-info
Text	https://www.congress.gov/116/bills/s2004/BILLS-116s2004is.pdf